$Therapeutic Compatibility of Orally Administered Racemic Ketamine with Modafinil, a CYP3A4 Enzyme Inducer, in Treatment-Refractory Major Depressive Disorder$

Therapeutic Compatibility of Orally Administered Racemic Ketamine with Modafinil, a CYP3A4 Enzyme Inducer, in Treatment-Refractory Major Depressive Disorder

Bibliographic Details
Main Author:	Chittaranjan Andrade
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-11-01
Series:	Indian Journal of Psychological Medicine
Online Access:	https://doi.org/10.1177/02537176231160264

Similar Items

Intravenous ketamine in refractory depression
by: Shivang Gandhi, et al.
Published: (2022-01-01)

Modafinil-excipient compatibility study using differential scanning calorimetry
by: Derar Omari, et al.
Published: (2023-01-01)

Minimum alveolar concentration of isoflurane in dogs administered a single intramuscular injection of racemic or S (+)-ketamine after premedication with acepromazine-morphine
by: Thais Feres Bressan, et al.

Esketamine Anesthetizes Mice With a Similar Potency to Racemic Ketamine
by: Xiaofan Ma, et al.
Published: (2023-02-01)

Ketamine vs electroconvulsive therapy: dissecting the surprises
by: Chittaranjan Andrade
Published: (2023-11-01)

Use of Modafinil in Psychiatric Disorders
by: Mehmet Hanifi Kokacya, et al.
Published: (2016-03-01)

Modafinil for multiple sclerosis fatigue: does it work?
by: Littleton, E, et al.
Published: (2010)

Modafinil decreases anxiety-like behaviour in zebrafish
by: Adrian Johnson, et al.
Published: (2017-02-01)

Case report: Improvement in refractory functional seizures, depression, and quality of life with ketamine-assisted therapy
by: Elena Argento, et al.
Published: (2023-06-01)

Stereoselective Pharmacokinetics of Ketamine Administered at a Low Dose in Awake Dogs
by: Gwenda Pargätzi, et al.
Published: (2024-03-01)

Response to ketamine treatment for major depressive disorder not associated with number of psychiatric comorbidities
by: Jamarie Geller, et al.
Published: (2024-01-01)

EEG-vigilance regulation is associated with and predicts ketamine response in major depressive disorder
by: Cheng-Teng Ip, et al.
Published: (2024-01-01)

Intravenous ketamine therapy in a patient with a treatment-resistant major depression
by: M Liebrenz, et al.
Published: (2007-04-01)

Effects of modafinil on emotional processing in first episode psychosis.
by: Scoriels, L, et al.
Published: (2011)

Simple Synthesis of Modafinil Derivatives and Their Anti-inflammatory Activity
by: Mankil Jung, et al.
Published: (2012-09-01)

Waking up to modafinil in shift work sleep disorder
by: Dilip Gude
Published: (2011-01-01)

The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder
by: Orli S. Schwartz, et al.
Published: (2023-10-01)

Comparison of tiletamine-zolazepam and tiletamine-zolazepam-ketamine-xylazine administered intravenously in dogs
by: Chen, Hui Cheng, et al.
Published: (2005)

Modafinil. Armodafinil. The use of eugeroics in assisting the treatment of depression, bipolar disorder, and schizophrenia. Benefits, drawbacks, and adverse effects
by: Norbert Kandefer, et al.
Published: (2023-08-01)

Should probiotics be administered as an adjunctive treatment along with antidepressants for major depressive disorder?
by: Haiqa Zulfiqar, et al.
Published: (2023-12-01)

Efficacy of Electroconvulsive Therapy and Ketamine Therapy in Major Depressive Disorder; A Comparative Study
by: Asif Azeem Bajwa, et al.
Published: (2023-02-01)

Ketamine for the treatment of major depression: a systematic review and meta-analysisResearch in context
by: Stevan Nikolin, et al.
Published: (2023-08-01)

EFFECT OF SINGLE DOSE OF KETAMINE IN PATIENTS OF MAJOR DEPRESSIVE DISORDER-A PAKISTANI PERSPECTIVE
by: Muhammad Siddique Kakar, et al.
Published: (2020-10-01)

The functional connectivity of the middle frontal cortex predicts ketamine’s outcome in major depressive disorder
by: Fan Zhang, et al.
Published: (2022-09-01)

Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.
by: Talbot, K, et al.
Published: (2003)

Positive effect of modafinil on daytime somnolence on patients with Myotonic Dystrophy
by: Talbot, K, et al.
Published: (2002)

Modafinil-induced drug reaction with eosinophilia and systemic symptoms syndrome
by: Stacy Y. Kasitinon, MD, PhD, et al.
Published: (2022-09-01)

Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions
by: Jonathan P Wisor
Published: (2013-10-01)

The efficacy and safety of ketamine in refractory and super-refractory status epilepticus: a systemic review
by: Khaled abdullah alzahrani, et al.
Published: (2023-06-01)

Refractory and super-refractory status epilepticus and evidence for the use of ketamine: a scope review
by: Luis Espinosa, et al.
Published: (2023-06-01)

Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects
by: Bhuvi Sachdeva, et al.
Published: (2023-03-01)

The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression
by: Julian Maciaszek, et al.
Published: (2023-08-01)

Genetic polymorphisms of cyp3a4 and cyp2c8 in heal thy volunteers administered with repaglinide
by: Gan Siew, Hua
Published: (2008)

Non-anaesthetist-administered ketamine for emergency caesarean section in Kenya: cost-effectiveness analysis
by: Sebastian Suarez, et al.
Published: (2022-10-01)

Functional connectivity of the amygdala subregions and the antidepressant effects of repeated ketamine infusions in major depressive disorder
by: Haiyan Liu, et al.
Published: (2024-01-01)

Effect of Acute Ketamine Treatment on Sympathetic Regulation Indexed by Electrodermal Activity in Adolescent Major Depression
by: Veronika Kovacova, et al.
Published: (2024-03-01)

Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder
by: Haiyan Liu, et al.
Published: (2023-02-01)

Therapeutic Potential of Orally Administered Rubiscolin-6
by: Yusuke Karasawa, et al.
Published: (2023-06-01)

Total Synthesis of the Racemate of Laurolitsine
by: Mingyu Cao, et al.
Published: (2024-02-01)

Structure of racemic duloxetine hydrochloride
by: Mohan M. Bhadbhade, et al.
Published: (2023-05-01)